Boehringer Ingelheim, a global leader in animal health, has partnered with Henke-Sass, Wolf (HSW) to develop an innovative, intramuscular, needle-free vaccine injection tool for pigs around weaning until the end of the nursery phase.
The novel device will be available to swine producers in most countries globally starting in December 2020 under two different brands: FreVAX (through Boehringer Ingelheim) and EPIG (through HSW), the announcement said.
Boehringer Ingelheim Animal Health head of swine Stephan Lange said, “Both FreVAX and EPIG fulfill the desire of swine producers to ensure safety of pigs and people as well as efficacy of vaccine application by avoiding broken needles and reducing pathogen transmission while increasing vaccination compliance, animal well-being and data availability and management. Our customers will truly benefit from this innovation.”
“Combining the technical skills and experience of a leading health technology company with the expertise of the global leader in swine vaccines has led to the development of a state-of-the-art innovative device addressing farmers’ needs for safe and efficacious vaccine administration,” added Stefan Knefel, vice president sales and marketing veterinary products at HSW.
Boehringer Ingelheim pointed out that FreVAX and EPIG replace conventional needle vaccination, ensuring smooth and painless intramuscular injections of 1 or 2 mL with no recoil, a low noise level and direct feedback for the user through intelligent sensors and LED alerts. These features have been incorporated to improve the vaccination experience for both the pig and the operator while offering vaccination compliance and reliability, the company said.
In addition, the product also provides smart functions for data capture and transfer.
All of this information as well as evaluation of vaccination quality can be accessed on smartphones thanks to a specifically designed app available for download from the Apple Store and Google Play Store.
HSW is a midsized, family-owned business and one of the leading medical technology companies in Germany. It produces a wide range of industrial products, medical and dental syringes as well as innovative veterinary products. The veterinary division in particular has experienced above-average growth in recent years and continues to focus on innovative products to improve future vaccination quality and animal welfare. More than 1,500 people work for HSW and its seven subsidiary companies.
Boehringer Ingelheim Animal Health is the second-largest animal health business in the world, with net sales of 4 billion euros in 2019 and a presence in more than 150 countries.